COVID-19 research
In light of the pandemic, we’ve devoted our protein and engineering expertise into understanding and developing therapy for SARS-CoV-2. Check out our publications and preprints:
-
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proceedings of the National Academy of Sciences. Nov 2020, 117 (45) 28046-28055.
-
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat Chem Biol. 17, 113–121 (2021).
-
Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding, mSphere. 2020 Sep 16; Vol. 5, No. 5.
-
Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection, Nat Biotechnol 39, 928–935 (2021).
-
Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity, BioRxiv, 2020.05.21.109157. Under review.
We are keenly focused on how cells remodel their extracellular proteome in health and disease. To understand and disrupt human disease-associated signaling processes, we develop enabling technologies with protein & antibody engineering and site-directed small molecule approaches.
